A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Glioblastoma
Interventions
DRUG

DSP-7888 Dosing Emulsion

DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.

DRUG

Bevacizumab

Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.

Trial Locations (61)

100

National Taiwan University Hospital, Taipei

10021

Weill Cornell Medicine, New York

10032

Columbia University Medical Center/ Neurological Institute of NY, New York

13620

Seoul National University Bundang Hospital, Seongnam-si

14226

Dent Neurosciences Research Center, Amherst

14642

University of Rochester Medical Center, Rochester

15232

University of Pittsburgh Medical Center (UPMC), Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

22031

Virginia Cancer Specialists, PC, Fairfax

30309

Piedmont brain tumor center, Atlanta

35294

University of Alabama at Birmingham, Birmingham

37920

University of Tennessee Academic Medical Center Cancer Institute, Knoxville

40202

Norton Cancer Institute, Louisville

40447

China Medical University Hospital, Taichung

40536

University of Kentucky / Department of Internal Medicine / Markey Cancer Center, Lexington

43606

University of Toledo, Toledo

44106

University Hospitals of Cleveland, Cleveland

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

48202

Henry Ford Health System, Detroit

53792

University of Wisconsin Hospital, Madison

55407

Abbott Northwestern Hospital, Minneapolis

60612

Rush University Medical Center, Chicago

72703

Highlands Oncology Group, Fayetteville

75246

Baylor Scott and White, Dallas

77030

Houston Methodist, Houston

Mischer Neuroscience Associates/Memorial Hermann Hospital, Houston

77380

Renovatio Clinical, The Woodlands

78705

Texas Oncology Austin Midtown, Austin

80218

Rocky Mountain Cancer Center, Denver

85718

Center for Neurosciences, Tucson

90027

Kaiser Permanente Los Angeles Medical Center, Los Angeles

90048

Cedars Sinai Medical Center, Los Angeles

90404

John Wayne Cancer Institute, Santa Monica

92093

UCSD- Moores Cancer Center, La Jolla

92868

Neuro-Oncology/ US Irvine Medical Center, Orange

93105

Sansum Clinic, Santa Barbara

98122

Swedish Medical Center, Seattle

02111

Tufts Medical Center, Boston

07601

Hackensack University Medical Center, Hackensack

02903

Rhode Island Hospital, Providence

R3E 0V9

CancerCare Manitoba, Winnipeg

H3A 2B4

Montreal Neurological Institute and Hospital, Montreal

J1H 5N4

University of Sherbrooke, Sherbrooke

060-8648

Hokkaido University Hospital, Sapporo

890-8520

Kagoshima University Hospital, Kagoshima

951-8520

Niigata University Medical and Dental Hospital, Chuo Ku

541-8567

Osaka International Cancer Institute, Chuo Ku

113-8655

The University of Tokyo Hospital, Bunkyo-ku

104-0045

National Cancer Center Hospital, Chuo-ku

734-8551

Hiroshima University Hospital, Hiroshima

860-8556

Kumamoto University Hospital, Kumamoto

602-8566

University Hospital, Kyoto Prefectural University of Medicine, Kyoto

612-8555

National Hospital Organization Kyoto Medical Center, Kyoto

162-8666

Tokyo Women's Medical University Hospital, Shinjuku-Ku

990-9585

Yamagata University Hospital, Yamagata

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

06273

Gangnam Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Unknown

Chang Gung Memorial Hospital, Taoyuan

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03149003 - A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | Biotech Hunter | Biotech Hunter